Risk factors associated with complications in patients with chemotherapy-induced febrile neutropenia in emergency department

Hematological Oncology

Volumn 31, Issue 4, 2013, Pages 189-196

  Lynn, Jiun Jen ^a   Chen, Kuan Fu ^a   Weng, Yi Ming ^a   Chiu, Te Fa ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Antibiotics; Chemotherapy; Complications; Febrile neutropenia; Prediction; Risk factors

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; CEFEPIME; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CELLULITIS; CHEMOTHERAPY INDUCED FEBRILE NEUTROPENIA; COHORT ANALYSIS; DECISION TREE; DISEASE ASSOCIATION; EMERGENCY WARD; ENTEROCOLITIS; FEBRILE NEUTROPENIA; FEMALE; HEART ARRHYTHMIA; HEMODYNAMIC PARAMETERS; HUMAN; HYPOTENSION; LATENT PERIOD; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION SYSTEM; MENTAL DISEASE; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY DISTRESS; RETROSPECTIVE STUDY; SEIZURE; SUDDEN DEATH; TERTIARY HEALTH CARE; THROMBOCYTE COUNT;

ANTIBIOTICS; CHEMOTHERAPY; COMPLICATIONS; FEBRILE NEUTROPENIA; PREDICTION; RISK FACTORS;

AGED; ANTI-BACTERIAL AGENTS; ARRHYTHMIAS, CARDIAC; CASE-CONTROL STUDIES; CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA; COINFECTION; COMORBIDITY; DIABETES COMPLICATIONS; DRUG ADMINISTRATION SCHEDULE; EMERGENCY SERVICE, HOSPITAL; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HOSPITAL MORTALITY; HUMANS; HYPOTENSION; MALE; MIDDLE AGED; MODELS, THEORETICAL; NEOPLASMS; PLATELET COUNT; PNEUMONIA; RESPIRATORY DISTRESS SYNDROME, ADULT; RETROSPECTIVE STUDIES; RISK FACTORS; ROC CURVE; SEPSIS; TAIWAN; TERTIARY CARE CENTERS;

EID: 84889099838     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.2040     Document Type: Article

References (24)

1. Friefeld AG, Pizzo PA. The outpatient management of febrile neutropenia in cancer patients. Oncology 1996; 10: 599-606.
2. Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 2005; 103: 1916-1924.
3. Moores KG. Safe and effective outpatient treatment of adults with chemotherapy-induced neutropenic fever. Am J Health-System Pharm 2007; 64: 717-722.
4. Morrison VA, Wong M, Hershman D, Campos LT, Ding B, Malin J. Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 304week chemotherapy regimens in community oncology practices. J Manage Care Pharm 2007; 13: 337-348.
5. Paesmans M, Klastersky J, Maertens J, et al. Predicting febrile neutropenic patients at low risk using the MASCC score: does bacteremia matter? Support Care Cancer 2011; 19: 1001-1008.
6. Debey C, Meert AP, Berghmans T, Thomas JM, Sculier JP. Febrile neutropenia at the emergency department of a cancer hospital. Rev Med Brux 2011; 32: 74-82.
7. Talcott JA, Finberg R, Mayer RJ, et al. The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Arch Intern Med 1988; 148: 2561-2568.
8. Klastersky J, Paesmans M, Rubenstrein EB, et al. The Multinational Association for Supportive Care of Cancer (Mascc) risk-index score: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000; 18: 3038-3051.
9. Hui EP, Leung LK, Poon TC, et al. Prediction of outcome in cancer patients with febrile neutropenia: a prospective validation of the Multinational Association for Supportive Care in Cancer risk index in a Chinese population and comparison with the Talcott model and artificial neural network. Support Care Cancer 2011; 19: 1625-1635.
10. Moon JM, Chun BJ. Predicting the complicated neutropenic fever in the emergency department. Emerg Med J 2000; 26: 802-806.
11. Persson LP, Soderquist B, Engervall P, et al. Assessment of inflammatory markers to differentiate a stable from a deteriorating clinical course in patients with febrile neutropenia. Eur J Haematol 2005; 74: 297-303.
12. Engl A, Knoll S, Kern P, Kern WV. Interleukin-8 serum levels at fever onset in patients with neutropenia predict early medical complications. Infection 2005; 33: 380-382.
13. Ulys A, Rapoport BL, Fickl H, Meyer PW, Anderson R. Prediction of outcome in cancer patients with febrile neutropenia: comparison of the Multinational Association of Supportive Care in Cancer risk-index score with procalcitonin, C-reactive protein, serum amyloid A, and interleukins-1beta, -6, -8 and -10. Eur J Cancer Care 2007; 16: 475-483.
14. Ahn S, Lee YS, Chun YH, et al. Predictive factors of poor prognosis in cancer patients with chemotherapy-induced febrile neutropenia. Support Care Cancer 2011; 19: 1151-1158.
15. Persson LP, Engerval P, Magnuson A, et al. Use of inflammatory markers for early detection of bacteraemia in patients with febrile neutropenia. Scand J Infect Dis 2004; 36: 365-371.
16. Viscoli C, Bruzzi P, Castagnola E, et al. Factors associated with bacteraemia in febrile, granulocytopenic cancer patients. The International Antimicrobial Theapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Canceer (EORTC). Eur J Cancer 1994; 30A: 430-437.
17. Hubel K, Hegener K, Schnell R, et al. Suppressed neutrophil function as a risk factor for severe infection after cytotoxic chemotherapy in patients with acute nonlymphocytic leukemia. Ann Hematol 1999; 78: 73-77.
18. André S, Taboulet P, Elie C, et al. Febrile neutropenia in French emergency departments: results of a prospective multicentre study. Crit Care 2010; 14: R68.
19. Erten M, Genc S, Besisik SK, et al. The predictive and diagnostic value of procalcitonin and C-reactive protein for clinical outcome in febrile neutropenic patients. J Chin Med Assoc 2004; 67: 217-221.
20. Ramzi J, Mohamed Z, Yosr B, Karima K, et al. Predictive factors of septic shock and mortality in neutropenic patients. Hematology 2007; 12: 543-548.
21. Lalami YM, Paesmans M, Muanza F, et al. Can we predict the duration of chemotherapy-induced neutropenia in febrile neutropenic patients, focusing on regimen-specific risk factors? A retrospective analysis. Ann Oncol 2006; 17: 507-514.
22. Chamilos GA, Bamias A, Efstathiou E, et al. Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin. Cancer 2005; 103: 2629-2635.
23. Innes HE, Smith DB, O'Reilly SM, Clark PI, Kelly V, Marshall E. Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study. Br J Cancer 2003; 89: 43-49.
24. Timmer-Bonte JN, de Boo TM, Smit HJ, et al. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study. J Clin Oncol 2005; 23: 7974-7984.